Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | NT5E | P21589 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | RORC | P51449 | 11/20 | 0.56 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.54 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.54 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892755 | 1.00 | GPBAR1 (0.64) | GPBAR1LMNANT5ESMN1; SMN2RORC | |
| SCHEMBL16986649 | 1.00 | GPBAR1 (0.64) | GPBAR1LMNANT5ESMN1; SMN2RORC | |
| SCHEMBL12558031 | 0.88 | RORC (0.72) | GPBAR1LMNANT5ERORCEGLN2 | |
| SCHEMBL12557918 | 0.85 | PRKCG (0.61) | NT5ERORC | |
| SCHEMBL9106728 | 0.83 | — | — | |
| SCHEMBL13628265 | 0.83 | GPBAR1 (0.64) | GPBAR1LMNANT5ESMN1; SMN2RORC | |
| SCHEMBL9891251 | 0.83 | RORC (0.56) | NT5ERORCEGLN2EGLN1EGLN3 | |
| SCHEMBL9109658 | 0.83 | GPBAR1 (0.72) | GPBAR1LMNANT5ESMN1; SMN2RORC | |
| SCHEMBL9108720 | 0.83 | GPBAR1 (0.72) | GPBAR1LMNANT5ESMN1; SMN2RORC | |
| SCHEMBL9107709 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802661-B2 | C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120142653-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142653-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | ERG28, BET1, BRD3 | GPBAR1 2177/4885LMNA 2335/4885NT5E 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.